Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule

PHASE3CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

February 16, 2004

Primary Completion Date

April 15, 2009

Study Completion Date

April 15, 2009

Conditions
Hepatitis BHepatitis A
Interventions
BIOLOGICAL

TWINRIX™ ADULT

2 doses IM injection in primary study

BIOLOGICAL

Engerix TM

If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.

Trial Locations (1)

2610

GSK Investigational Site, Wilrijk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY